<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138424</url>
  </required_header>
  <id_info>
    <org_study_id>04-047</org_study_id>
    <secondary_id>CASG 209</secondary_id>
    <nct_id>NCT00138424</nct_id>
  </id_info>
  <brief_title>Cidofovir in Renal Transplant Recipients With BKVN</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This study will look at the safety, tolerability and effectiveness of cidofovir in kidney
      transplant patients who have been diagnosed with BK virus nephropathy (BKVN), a viral
      condition that can cause patients to reject transplanted kidneys. Up to 48 adult (age 18
      years and older) kidney or pancreas transplant recipients with newly diagnosed BKVN will
      receive 1 of 3 cidofovir dose levels or placebo (non medicated substance) to identify the
      maximum tolerated dose. Dosing will be administered intravenously (by a tube running into a
      blood vessel). In addition to the screening visit, volunteers will actively participate for
      approximately 8-10 weeks with a single follow up phone call at 4 months. Blood samples, urine
      samples, eye exams and physical exams are included in study procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this randomized, double-blind, placebo-controlled, dose-escalation
      study are to evaluate the safety and tolerability of 3 dose levels of cidofovir when
      administered to renal transplant recipients with BK virus nephropathy and to identify the
      maximum tolerated doses (MTD) among the 3 dose levels of cidofovir in renal transplant
      recipients with BK virus nephropathy. The secondary study objectives are to evaluate the
      antiviral effect of cidofovir at each of 3 dose levels; to evaluate the pharmacokinetics (PK)
      of cidofovir in renal transplant recipients with underlying renal impairment; to evaluate the
      pharmacodynamics (PD) of cidofovir in this setting; to evaluate allograft function at the
      completion of the study; and to assess allograft rejection at the completion of the study.
      Patients with BKVN (virus nephropathy) diagnosed by positive plasma polymerase chain reaction
      (PCR) or renal allograft biopsy will be randomized to receive study drug within 60 days of
      the date of the renal biopsy or plasma PCR assay that established the diagnosis of BKVN. The
      study consists of three dose cohorts (0.25 mg/kg, 0.5 mg/kg and 1.0 mg/kg); each cohort will
      consist of approximately 12 subjects randomized 2:1 to receive either cidofovir or placebo
      (0.9% normal saline) to define the MTD among the three specified doses of cidofovir. Once the
      MTD is established, approximately 12 additional patients will be enrolled at that dose. The
      MTD is defined as the dose in which no more than 2 of the 8 cidofovir treated subjects
      experience a dose limiting toxicity (DLT). The target enrollment is 48 subjects if all dose
      cohorts are fully enrolled. A 25% over-enrollment may be tolerated to allow for continued
      enrollment of subjects in the lower dose cohort if data are under concomitant review by the
      Data and Safety Monitoring Board (DSMB) or to replace non-evaluable study participants. Study
      participants who have been randomized and have received cidofovir/placebo (in any cohort)
      will be considered non-evaluable if they discontinue from the study or die for any reason
      except toxicities definitely related to study treatment, including DLTs. These subjects may
      be replaced. There will be a 5-week drug administration period (4 doses) followed by a 2 week
      end-of-study observation and evaluation period for each cohort. At about 3 months after last
      dose of study infusion, a member of the research staff will assess the study participant and
      counsel on pregnancy status via a phone call. The study will be overseen by a DSMB who will
      review the data after each dose cohort is completed. The primary endpoint of the study will
      assess the safety and tolerability of cidofovir in kidney transplant recipients this will be
      assessed by enumeration of adverse events (AEs) reported by the subjects and/or investigator,
      and changes observed in the physical examination (including vital signs) and laboratory
      evaluations during the drug administration and end-of-treatment observation and evaluation
      periods. The severity and relationship of AEs to receipt of study drug will be determined
      because the primary endpoint is focusing on the safety. The secondary endpoints are the
      effect of cidofovir on BK virus as determined by: percentage of subjects who achieve an
      undetectable BK virus urine and plasma PCR between baseline and end of treatment; rate of
      reduction in urine and plasma BK virus load by quantitative PCR between baseline and end of
      treatment; and time to reduction in BK virus urine and plasma PCR; the detailed PK of
      cidofovir will be evaluated in subjects at the MTD; the PD of cidofovir will be assessed by
      quantitating the change in BK virus deoxyribonucleic aci
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Cidofovir Assessed by Enumeration of Adverse Events Per Subject</measure>
    <time_frame>Baseline through day 49</time_frame>
    <description>The measure is the number of adverse events (ie: events that are change from baseline)experienced by subjects. The median or average number of events and the range of events across all subjects is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events by Grade of Event</measure>
    <time_frame>Baseline through day 49.</time_frame>
    <description>Adverse events are reported as grades:
Toxicity Grade I: a mild event (an event that requires minimal or no treatment and does not interfere with the subject's daily activities.
Toxicity Grade II: a moderate event (an event that results in a low level of inconvenience or concern with the therapeutic measures and may cause some interference with functioning.
Toxicity Grade III: a severe event (an event that interrupts a subject's usual daily activity and may require systemic drug therapy or other treatment and may be incapacitating.
Toxicity Grade IV: Life threatening (any adverse drug experience that places the patient or subject at immediate risk of death from the reaction as it occurred)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Related Adverse Events</measure>
    <time_frame>Baseline through day 49.</time_frame>
    <description>The investigator's assessment of an AE's relationship to study drug is part of the documentation process. All adverse events had their relationship to study product assessed using the following terms: associated (related)or not associated (not related). To help assess, the following guidelines were used.
Associated - There was a known temporal relationship and/or, if re-challenge was done, the event abates with de-challenge and reappears with re-challenge and/or the event was known to occur in association study product or with a product in a similar class of study products
Not Associated -the AE was completely independent of study product administration; and/or evidence existed that the event was definitely related to another etiology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes Observed in the Physical Examination : Respiratory Rate (Per Minute)</measure>
    <time_frame>Baseline through day 49.</time_frame>
    <description>Respiratory rate is the number of breaths per minute.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes Observed in the Physical Examination: Blood Pressure (mm/hg)</measure>
    <time_frame>Baseline through day 49.</time_frame>
    <description>Blood pressure (BP) is the pressure exerted by circulating blood upon the walls of blood vessels. &quot;Blood pressure&quot; usually refers to the arterial pressure of the systemic circulation. During each heartbeat, blood pressure varies between a maximum (systolic) and a minimum (diastolic) pressure. The measure is the difference between the baseline systolic and baseline diastolic value with the day 49 systolic and day 49 diastolic value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes Observed in the Physical Examination: Body Temperature (Fahrenheit)</measure>
    <time_frame>Baseline through day 49.</time_frame>
    <description>The temperature is a measure of body temperature in fahrenheit (F). The measure is a change between baseline temperature and day 49 temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes Observed in the Physical Examination: Heart Rate (Per Minute)</measure>
    <time_frame>Baseline through day 49.</time_frame>
    <description>The heart rate is the number of heart beats per minute. The outcome measure is the change from baseline heart rate to day 49 heart rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Experiencing at Least One Laboratory Abnormality</measure>
    <time_frame>Baseline through day 49</time_frame>
    <description>The following lab values assessed during the 49 days of subject involvement were the following: hemoglobin, hematocrit, platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), serum creatinine, calcium, phosphorous, serum albumin, glucose, uric acid, magnesium, total protein, total bilirubin, alanine aminotransferase (ALT), asparate aminotransferase (AST) and alkaline phosphate. The outcome measure is the number of subjects experiencing at least 1 grade 1 (mild) or higher event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effect of Cidofovir on BK Virus Determined by Percentage of Subjects Achieving an Undetectable BK Virus in Urine and Plasma PCR</measure>
    <time_frame>Day 35.</time_frame>
    <description>The outcome measure is the percent of subjects that achieved non-detectable BK virus in the urine and plasma polymerase chain reaction (PCR) at day 35 after staring study drug. Undetectable is a PCR viral load of less than 200.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Viral Load in Urine and Plasma BK Virus by Quantitative PCR Between Baseline and Each Visit</measure>
    <time_frame>Baseline, and each visit: day 7, 21, 35 and 49.</time_frame>
    <description>The percent change in viral load from baseline to day 7, day 21 and day 49 as measured in the urine and measured in the blood. A drop is identified by use of '-', an increase in viral load has no sign in front of the number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Achieving 50% Reduction Viral Load in Plasma and Urine</measure>
    <time_frame>Baseline through day 49.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days to at Least 50% Reduction of Viral Load in Plasma and Urine</measure>
    <time_frame>Baseline through day 49.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allograft Function at the Completion of the Study</measure>
    <time_frame>Day 49.</time_frame>
    <description>Glomerular filtration rate (GFR) is a test used to check how well the kidneys are working. Specifically, it estimates how much blood passes through the tiny filters in the kidneys, called glomeruli, each minute. The normal health GFR is about 90 - 120 mL/min/1.73 m2. Older people will have lower normal GFR levels, because GFR decreases with age.
Abnormal Results are expected to be below 60 mL/min/1.73 m2 for 3 or more months are a sign of chronic kidney disease. A GFR result below 15 mL/min/1.73 m2 may be a sign of kidney failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allograft Rejection.</measure>
    <time_frame>Day 49.</time_frame>
    <description>Allograft rejection is the number of subjects that rejected their kidney by the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacodynamics of Cidofovir Will be Assessed by Correlating the Percent Change in BK Virus DNA in Urine and Plasma With Pharmacokinetic Changes Between Baseline Through Day 35</measure>
    <time_frame>Baseline through day 35</time_frame>
    <description>PK parameter change from baseline to day 35 for Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacodynamics of Cidofovir Will be Assessed by Correlating the Percent Change in BK Virus DNA in Urine and Plasma With Pharmacokinetic Changes Between Baseline and Day 35</measure>
    <time_frame>Baseline through day 35</time_frame>
    <description>PK parameter change from baseline to day 35 for AUC4 and AUC12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>BK Virus (Nephropathy)</condition>
  <arm_group>
    <arm_group_label>Cidofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 subjects will be randomized to 1 of 3 possible cohorts. Cohort I will receive dose 0.25 mg/kg; Cohort II will receive 0.5 mg/kg, Cohort III will receive 1.0 mg/kg. Maximum tolerated dose is to be determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>16 subjects to receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cidofovir</intervention_name>
    <description>Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.</description>
    <arm_group_label>Cidofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The control for this study is sterile, 0.9% normal saline for intravenous use.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged greater than or equal to 18 years.

          -  Kidney or kidney/pancreas transplant recipient.

          -  New onset BK Virus Nephropathy (BKVN) diagnosed by a positive plasma polymerase chain
             reaction (PCR) assay for BK virus deoxyribonucleic acid (DNA) or by a renal biopsy
             demonstrating BK virus (by immunohistochemistry, electron microscopy and/or in situ
             hybridization) obtained as part of standard medical care within 60 days prior to
             receipt of first dose of study drug.

          -  BK virus load in plasma greater than 10,000 copies/mL within prior 21 days.

          -  Glomerular filtration rate greater than 30 mL/min using Levey calculations.

          -  Absolute neutrophil count greater than 1000/microliter [with granulocyte colony
             stimulating factor (GCSF) support as necessary].

          -  Women must be post-menopausal, surgically sterile or willing to use adequate
             contraception (barrier method with spermicide, intrauterine device, oral
             contraceptives, implant or other licensed hormone method) from time of study
             enrollment through 1 month after the last dose of study treatment. Men must be
             surgically sterile or willing to use contraception (barrier method with spermicide)
             from time of study enrollment through 3 months after the last dose of study treatment.

        Exclusion Criteria:

          -  Unable to provide valid informed consent.

          -  History of intolerance to cidofovir or related compounds (i.e. other nucleotide
             derivatives [adefovir or tenofovir]).

          -  Pregnant or breast feeding women.

          -  Prior treatment with cidofovir within the last 2 weeks.

          -  Receipt of another investigational drug with proven nephrotoxic drug interaction with
             cidofovir or known antipolyoma virus activity one month prior to study entry.

          -  Contraindication to renal biopsy (e.g., anticoagulant medication, unwilling to undergo
             biopsy).

          -  Currently receiving or anticipated to receive any of the following within 2 weeks of
             randomization:

          -  Amphotericin preparation (intravenous)

          -  Aminoglycosides (intravenous)

          -  Platinum - based chemotherapeutic agents

          -  NSAIDs - non steroidal anti-inflammatory drugs (aspirin given for cardioprotective
             treatment is acceptable up to 650 mg per oral daily)

          -  Foscarnet

          -  Pentamidine (intravenous)

          -  Probenecid

          -  Leflunomide

          -  Hypotony or uveitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama Hospital - Nephrology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center - Sutter Pacific Medical Foundation - Transplant Nephrology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-1932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center at Parnassus - Organ Transplant</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-2204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-2541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Comprehensive Transplant Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center - Kindney Trasnplant - Nephrology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1447</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455-0356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Rochester - Infectious Diseases</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center - Infectious Disease</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Nephrology Associates - Dallas Transplant Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204-6168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington - Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-7110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics - Clinical Science Center - Nephrology</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <results_first_submitted>June 14, 2012</results_first_submitted>
  <results_first_submitted_qc>November 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 7, 2013</results_first_posted>
  <disposition_first_submitted>September 22, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>September 22, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2011</disposition_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VistideÂ®, Cidofovir, renal transplant, BK Virus Nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cidofovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort I - Cidofovir</title>
          <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
        <group group_id="P2">
          <title>Cohort I - Placebo</title>
          <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
        <group group_id="P3">
          <title>Cohort II - Cidofovir</title>
          <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
        <group group_id="P4">
          <title>Cohort II - Placebo</title>
          <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort I - Cidofovir</title>
          <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
        <group group_id="B2">
          <title>Cohort I - Placebo</title>
          <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
        <group group_id="B3">
          <title>Cohort II - Cidofovir</title>
          <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
        <group group_id="B4">
          <title>Cohort II - Placebo</title>
          <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 30 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 70 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Cidofovir Assessed by Enumeration of Adverse Events Per Subject</title>
        <description>The measure is the number of adverse events (ie: events that are change from baseline)experienced by subjects. The median or average number of events and the range of events across all subjects is reported.</description>
        <time_frame>Baseline through day 49</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Cidofovir Assessed by Enumeration of Adverse Events Per Subject</title>
          <description>The measure is the number of adverse events (ie: events that are change from baseline)experienced by subjects. The median or average number of events and the range of events across all subjects is reported.</description>
          <units>Event</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O3" value="3" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O4" value="7" lower_limit="2" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of Cidofovir on BK Virus Determined by Percentage of Subjects Achieving an Undetectable BK Virus in Urine and Plasma PCR</title>
        <description>The outcome measure is the percent of subjects that achieved non-detectable BK virus in the urine and plasma polymerase chain reaction (PCR) at day 35 after staring study drug. Undetectable is a PCR viral load of less than 200.</description>
        <time_frame>Day 35.</time_frame>
        <population>Percentage of subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Cidofovir on BK Virus Determined by Percentage of Subjects Achieving an Undetectable BK Virus in Urine and Plasma PCR</title>
          <description>The outcome measure is the percent of subjects that achieved non-detectable BK virus in the urine and plasma polymerase chain reaction (PCR) at day 35 after staring study drug. Undetectable is a PCR viral load of less than 200.</description>
          <population>Percentage of subjects</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Viral Load in Urine and Plasma BK Virus by Quantitative PCR Between Baseline and Each Visit</title>
        <description>The percent change in viral load from baseline to day 7, day 21 and day 49 as measured in the urine and measured in the blood. A drop is identified by use of '-', an increase in viral load has no sign in front of the number.</description>
        <time_frame>Baseline, and each visit: day 7, 21, 35 and 49.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Viral Load in Urine and Plasma BK Virus by Quantitative PCR Between Baseline and Each Visit</title>
          <description>The percent change in viral load from baseline to day 7, day 21 and day 49 as measured in the urine and measured in the blood. A drop is identified by use of '-', an increase in viral load has no sign in front of the number.</description>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7 Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="-195.2" upper_limit="60.7"/>
                    <measurement group_id="O2" value="61.9" lower_limit="-17.3" upper_limit="99.8"/>
                    <measurement group_id="O3" value="21.2" lower_limit="2.5" upper_limit="70.1"/>
                    <measurement group_id="O4" value="7.9" lower_limit="-268.8" upper_limit="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="-149.3" upper_limit="87.9"/>
                    <measurement group_id="O2" value="19.1" lower_limit="-55299.7" upper_limit="80.0"/>
                    <measurement group_id="O3" value="-3.1" lower_limit="-319.5" upper_limit="26.5"/>
                    <measurement group_id="O4" value="1.6" lower_limit="-579.6" upper_limit="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" lower_limit="-387.5" upper_limit="88.1"/>
                    <measurement group_id="O2" value="75.6" lower_limit="-75.6" upper_limit="99.8"/>
                    <measurement group_id="O3" value="58.4" lower_limit="-6.3" upper_limit="89.4"/>
                    <measurement group_id="O4" value="53.9" lower_limit="-174.9" upper_limit="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="-3.7" upper_limit="99.6"/>
                    <measurement group_id="O2" value="26.2" lower_limit="-108553.1" upper_limit="94.5"/>
                    <measurement group_id="O3" value="8.1" lower_limit="-102.1" upper_limit="60.1"/>
                    <measurement group_id="O4" value="11.1" lower_limit="-63.6" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" lower_limit="-295.2" upper_limit="93.3"/>
                    <measurement group_id="O2" value="91.3" lower_limit="2.7" upper_limit="99.8"/>
                    <measurement group_id="O3" value="76.2" lower_limit="35.9" upper_limit="93.2"/>
                    <measurement group_id="O4" value="83.3" lower_limit="-402.0" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" lower_limit="-32.1" upper_limit="99.7"/>
                    <measurement group_id="O2" value="29.9" lower_limit="-88968.7" upper_limit="97.8"/>
                    <measurement group_id="O3" value="25.5" lower_limit="3.2" upper_limit="76.8"/>
                    <measurement group_id="O4" value="8.3" lower_limit="-7.1" upper_limit="92.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 49 Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" lower_limit="-22.8" upper_limit="96.5"/>
                    <measurement group_id="O2" value="95.0" lower_limit="-72.4" upper_limit="99.6"/>
                    <measurement group_id="O3" value="76.7" lower_limit="15.8" upper_limit="91.3"/>
                    <measurement group_id="O4" value="65.1" lower_limit="-1094.4" upper_limit="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 49 Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" lower_limit="-142.3" upper_limit="99.8"/>
                    <measurement group_id="O2" value="86.1" lower_limit="-65494.3" upper_limit="95.8"/>
                    <measurement group_id="O3" value="-0.7" lower_limit="-31.1" upper_limit="86.5"/>
                    <measurement group_id="O4" value="12.9" lower_limit="-51.5" upper_limit="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Achieving 50% Reduction Viral Load in Plasma and Urine</title>
        <time_frame>Baseline through day 49.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Achieving 50% Reduction Viral Load in Plasma and Urine</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Subjects at 50% Reduction in Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Subject at 50% Reduction in Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days to at Least 50% Reduction of Viral Load in Plasma and Urine</title>
        <time_frame>Baseline through day 49.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days to at Least 50% Reduction of Viral Load in Plasma and Urine</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="7" upper_limit="51"/>
                    <measurement group_id="O2" value="7.5" lower_limit="7" upper_limit="21"/>
                    <measurement group_id="O3" value="22" lower_limit="7" upper_limit="50"/>
                    <measurement group_id="O4" value="20.5" lower_limit="20" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="7" upper_limit="21"/>
                    <measurement group_id="O2" value="35" lower_limit="7" upper_limit="49"/>
                    <measurement group_id="O3" value="29" lower_limit="22" upper_limit="36"/>
                    <measurement group_id="O4" value="20" lower_limit="20" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events by Grade of Event</title>
        <description>Adverse events are reported as grades:
Toxicity Grade I: a mild event (an event that requires minimal or no treatment and does not interfere with the subject's daily activities.
Toxicity Grade II: a moderate event (an event that results in a low level of inconvenience or concern with the therapeutic measures and may cause some interference with functioning.
Toxicity Grade III: a severe event (an event that interrupts a subject's usual daily activity and may require systemic drug therapy or other treatment and may be incapacitating.
Toxicity Grade IV: Life threatening (any adverse drug experience that places the patient or subject at immediate risk of death from the reaction as it occurred)</description>
        <time_frame>Baseline through day 49.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events by Grade of Event</title>
          <description>Adverse events are reported as grades:
Toxicity Grade I: a mild event (an event that requires minimal or no treatment and does not interfere with the subject's daily activities.
Toxicity Grade II: a moderate event (an event that results in a low level of inconvenience or concern with the therapeutic measures and may cause some interference with functioning.
Toxicity Grade III: a severe event (an event that interrupts a subject's usual daily activity and may require systemic drug therapy or other treatment and may be incapacitating.
Toxicity Grade IV: Life threatening (any adverse drug experience that places the patient or subject at immediate risk of death from the reaction as it occurred)</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grad3 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Related Adverse Events</title>
        <description>The investigatorâs assessment of an AE's relationship to study drug is part of the documentation process. All adverse events had their relationship to study product assessed using the following terms: associated (related)or not associated (not related). To help assess, the following guidelines were used.
Associated â There was a known temporal relationship and/or, if re-challenge was done, the event abates with de-challenge and reappears with re-challenge and/or the event was known to occur in association study product or with a product in a similar class of study products
Not Associated -the AE was completely independent of study product administration; and/or evidence existed that the event was definitely related to another etiology.</description>
        <time_frame>Baseline through day 49.</time_frame>
        <population>Number of Related Events</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Related Adverse Events</title>
          <description>The investigatorâs assessment of an AE's relationship to study drug is part of the documentation process. All adverse events had their relationship to study product assessed using the following terms: associated (related)or not associated (not related). To help assess, the following guidelines were used.
Associated â There was a known temporal relationship and/or, if re-challenge was done, the event abates with de-challenge and reappears with re-challenge and/or the event was known to occur in association study product or with a product in a similar class of study products
Not Associated -the AE was completely independent of study product administration; and/or evidence existed that the event was definitely related to another etiology.</description>
          <population>Number of Related Events</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes Observed in the Physical Examination : Respiratory Rate (Per Minute)</title>
        <description>Respiratory rate is the number of breaths per minute.</description>
        <time_frame>Baseline through day 49.</time_frame>
        <population>subjects whose respiratory rate was measured at baseline visit and at day 49 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Observed in the Physical Examination : Respiratory Rate (Per Minute)</title>
          <description>Respiratory rate is the number of breaths per minute.</description>
          <population>subjects whose respiratory rate was measured at baseline visit and at day 49 visit.</population>
          <units>Change in Breaths per Minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-4" upper_limit="6"/>
                    <measurement group_id="O2" value="0" lower_limit="-4" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="-4" upper_limit="2"/>
                    <measurement group_id="O4" value="-2" lower_limit="-4" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes Observed in the Physical Examination: Blood Pressure (mm/hg)</title>
        <description>Blood pressure (BP) is the pressure exerted by circulating blood upon the walls of blood vessels. &quot;Blood pressure&quot; usually refers to the arterial pressure of the systemic circulation. During each heartbeat, blood pressure varies between a maximum (systolic) and a minimum (diastolic) pressure. The measure is the difference between the baseline systolic and baseline diastolic value with the day 49 systolic and day 49 diastolic value.</description>
        <time_frame>Baseline through day 49.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Observed in the Physical Examination: Blood Pressure (mm/hg)</title>
          <description>Blood pressure (BP) is the pressure exerted by circulating blood upon the walls of blood vessels. &quot;Blood pressure&quot; usually refers to the arterial pressure of the systemic circulation. During each heartbeat, blood pressure varies between a maximum (systolic) and a minimum (diastolic) pressure. The measure is the difference between the baseline systolic and baseline diastolic value with the day 49 systolic and day 49 diastolic value.</description>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="-31" upper_limit="38"/>
                    <measurement group_id="O2" value="-4" lower_limit="-8" upper_limit="51"/>
                    <measurement group_id="O3" value="-3" lower_limit="-17" upper_limit="39"/>
                    <measurement group_id="O4" value="3" lower_limit="-46" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-14" upper_limit="1"/>
                    <measurement group_id="O2" value="6" lower_limit="2" upper_limit="14"/>
                    <measurement group_id="O3" value="10" lower_limit="-8" upper_limit="22"/>
                    <measurement group_id="O4" value="-4" lower_limit="-25" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Allograft Function at the Completion of the Study</title>
        <description>Glomerular filtration rate (GFR) is a test used to check how well the kidneys are working. Specifically, it estimates how much blood passes through the tiny filters in the kidneys, called glomeruli, each minute. The normal health GFR is about 90 - 120 mL/min/1.73 m2. Older people will have lower normal GFR levels, because GFR decreases with age.
Abnormal Results are expected to be below 60 mL/min/1.73 m2 for 3 or more months are a sign of chronic kidney disease. A GFR result below 15 mL/min/1.73 m2 may be a sign of kidney failure.</description>
        <time_frame>Day 49.</time_frame>
        <population>subjects that had GFR at each visit last visit</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Allograft Function at the Completion of the Study</title>
          <description>Glomerular filtration rate (GFR) is a test used to check how well the kidneys are working. Specifically, it estimates how much blood passes through the tiny filters in the kidneys, called glomeruli, each minute. The normal health GFR is about 90 - 120 mL/min/1.73 m2. Older people will have lower normal GFR levels, because GFR decreases with age.
Abnormal Results are expected to be below 60 mL/min/1.73 m2 for 3 or more months are a sign of chronic kidney disease. A GFR result below 15 mL/min/1.73 m2 may be a sign of kidney failure.</description>
          <population>subjects that had GFR at each visit last visit</population>
          <units>mL/min/1.73 m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" lower_limit="26.5" upper_limit="72.9"/>
                    <measurement group_id="O2" value="40.3" lower_limit="30.0" upper_limit="57.8"/>
                    <measurement group_id="O3" value="45.1" lower_limit="36.1" upper_limit="90.5"/>
                    <measurement group_id="O4" value="63.2" lower_limit="22.6" upper_limit="84.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Allograft Rejection.</title>
        <description>Allograft rejection is the number of subjects that rejected their kidney by the end of the study.</description>
        <time_frame>Day 49.</time_frame>
        <population>Number of rejections</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Allograft Rejection.</title>
          <description>Allograft rejection is the number of subjects that rejected their kidney by the end of the study.</description>
          <population>Number of rejections</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes Observed in the Physical Examination: Body Temperature (Fahrenheit)</title>
        <description>The temperature is a measure of body temperature in fahrenheit (F). The measure is a change between baseline temperature and day 49 temperature.</description>
        <time_frame>Baseline through day 49.</time_frame>
        <population>Subject's last visit minus baseline visit</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Observed in the Physical Examination: Body Temperature (Fahrenheit)</title>
          <description>The temperature is a measure of body temperature in fahrenheit (F). The measure is a change between baseline temperature and day 49 temperature.</description>
          <population>Subject's last visit minus baseline visit</population>
          <units>Temperature (F)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="-1.82" upper_limit="0.18"/>
                    <measurement group_id="O2" value="0.72" lower_limit="-0.54" upper_limit="60.46"/>
                    <measurement group_id="O3" value="-0.42" lower_limit="-1" upper_limit="0.5"/>
                    <measurement group_id="O4" value="0.3" lower_limit="-0.7" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes Observed in the Physical Examination: Heart Rate (Per Minute)</title>
        <description>The heart rate is the number of heart beats per minute. The outcome measure is the change from baseline heart rate to day 49 heart rate.</description>
        <time_frame>Baseline through day 49.</time_frame>
        <population>Subject's whose heart rate was measured at baseline and day 49 visit</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Observed in the Physical Examination: Heart Rate (Per Minute)</title>
          <description>The heart rate is the number of heart beats per minute. The outcome measure is the change from baseline heart rate to day 49 heart rate.</description>
          <population>Subject's whose heart rate was measured at baseline and day 49 visit</population>
          <units>Change in Beats per Minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" lower_limit="-22" upper_limit="1"/>
                    <measurement group_id="O2" value="3" lower_limit="-17" upper_limit="13"/>
                    <measurement group_id="O3" value="4" lower_limit="-14" upper_limit="21"/>
                    <measurement group_id="O4" value="-4" lower_limit="-7" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Experiencing at Least One Laboratory Abnormality</title>
        <description>The following lab values assessed during the 49 days of subject involvement were the following: hemoglobin, hematocrit, platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), serum creatinine, calcium, phosphorous, serum albumin, glucose, uric acid, magnesium, total protein, total bilirubin, alanine aminotransferase (ALT), asparate aminotransferase (AST) and alkaline phosphate. The outcome measure is the number of subjects experiencing at least 1 grade 1 (mild) or higher event.</description>
        <time_frame>Baseline through day 49</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort I - Placebo</title>
            <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O3">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O4">
            <title>Cohort II - Placebo</title>
            <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing at Least One Laboratory Abnormality</title>
          <description>The following lab values assessed during the 49 days of subject involvement were the following: hemoglobin, hematocrit, platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), serum creatinine, calcium, phosphorous, serum albumin, glucose, uric acid, magnesium, total protein, total bilirubin, alanine aminotransferase (ALT), asparate aminotransferase (AST) and alkaline phosphate. The outcome measure is the number of subjects experiencing at least 1 grade 1 (mild) or higher event.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WBC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Albumin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (SGPT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (SGOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacodynamics of Cidofovir Will be Assessed by Correlating the Percent Change in BK Virus DNA in Urine and Plasma With Pharmacokinetic Changes Between Baseline Through Day 35</title>
        <description>PK parameter change from baseline to day 35 for Cmax.</description>
        <time_frame>Baseline through day 35</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week - days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week - days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacodynamics of Cidofovir Will be Assessed by Correlating the Percent Change in BK Virus DNA in Urine and Plasma With Pharmacokinetic Changes Between Baseline Through Day 35</title>
          <description>PK parameter change from baseline to day 35 for Cmax.</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.4" lower_limit="-212.2" upper_limit="5173.9"/>
                    <measurement group_id="O2" value="-233.9" lower_limit="-338.3" upper_limit="242.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in plasma vs the PK Cmax parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>0.24</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in urine vs the PK Cmax parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>0.26</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in plasma vs the PK Cmax parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>-0.30</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in urine vs the PK Cmax parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>0.80</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacodynamics of Cidofovir Will be Assessed by Correlating the Percent Change in BK Virus DNA in Urine and Plasma With Pharmacokinetic Changes Between Baseline and Day 35</title>
        <description>PK parameter change from baseline to day 35 for AUC4 and AUC12</description>
        <time_frame>Baseline through day 35</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort I - Cidofovir</title>
            <description>One dose (0.25 mg/kg/week - days 0, 7, 21, 35, 49)</description>
          </group>
          <group group_id="O2">
            <title>Cohort II - Cidofovir</title>
            <description>One dose (0.5 mg/kg/week - days 0, 7, 21, 35, 49)</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacodynamics of Cidofovir Will be Assessed by Correlating the Percent Change in BK Virus DNA in Urine and Plasma With Pharmacokinetic Changes Between Baseline and Day 35</title>
          <description>PK parameter change from baseline to day 35 for AUC4 and AUC12</description>
          <units>hr*mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-0.5" upper_limit="3.9"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.5" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.7" upper_limit="4.2"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.5" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in plasma vs the PK AUC4 parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>0.07</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in urine vs the PK AUC4 parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>0.31</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in plasma vs the PK AUC4 parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>-0.41</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in urine vs the PK AUC4 parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>0.87</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in plasma vs the PK AUC12 parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>0.12</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in urine vs the PK AUC12 parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>0.52</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in plasma vs the PK AUC12 parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>0.20</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Spearman correlation co-efficient utilized to determine viral load changes in urine vs the PK AUC12 parameter</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>0.20</param_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs were reported within one business day of awareness of the event by completing Serious Adverse Event Report. Events were reported from start of study drug use to end of study..</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort I - Cidofovir</title>
          <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
        <group group_id="E2">
          <title>Cohort I - Placebo</title>
          <description>One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
        <group group_id="E3">
          <title>Cohort II - Cidofovir</title>
          <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
        <group group_id="E4">
          <title>Cohort II - Placebo</title>
          <description>One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transplant Rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>White blood cell disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infusion site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transplant Rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Eye burns</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study closed early due to failure to enroll in a timely manner.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Penelope Jester, BSN,MPH,CCRC</name_or_title>
      <organization>Collaborative Antiviral Study Group</organization>
      <phone>(205) 877-975-7280</phone>
      <email>PJester@peds.uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

